US approves groundbreaking mRNA flu vaccine for adults 50+
TL;DR Summary
The FDA approved Moderna’s first mRNA-based flu vaccine (mFLUSIVA) for adults 50 and older—the first of its kind—with a study of over 40,000 participants showing about 27% higher effectiveness than standard seasonal flu shots during the 2024–25 season. Moderna expects a fall rollout, with the CDC’s advisory committee expected to weigh in on a formal immunization recommendation after unanimously supporting the vaccine’s benefits for older adults.
- FDA approves first mRNA-based flu vaccine CNN
- F.D.A. Approves Moderna’s mRNA Flu Vaccine The New York Times
- FDA Approves First MRNA Flu Vaccine For Older Adults Forbes
- FDA approves 1st mRNA flu shot, from Moderna NBC News
- U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech NPR
Reading Insights
Total Reads
1
Unique Readers
7
Time Saved
200 min
vs 201 min read
Condensed
100%
40,091 → 66 words
Want the full story? Read the original article
Read on CNN